Risk, consent, and SUPPORT

New England Journal of Medicine

Volumn 368, Issue 20, 2013, Pages 1864-1865

  Magnus, David ^a   Caplan, Arthur L ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN;

BLINDNESS; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; HEALTH CARE QUALITY; HUMAN; INFORMED CONSENT; MEDICAL DOCUMENTATION; MEDICAL RESEARCH; NERVOUS SYSTEM INJURY; NEWBORN DEATH; NEWBORN MORTALITY; OXYGEN SATURATION; PATIENT CARE; PATIENT INFORMATION; PHYSICIAN ATTITUDE; PREMATURITY; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; RISK ASSESSMENT; SHORT SURVEY; STANDARD; STUDY DESIGN; TREATMENT PLANNING;

EID: 84877770702     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1305086     Document Type: Article

References (5)

1. Fiore LD, Brophy M, Ferguson RE, et al. A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimen. Clin Trials 2011;8:183-95.
2. Drazen JM, Solomon CG, Greene MF. Informed consent and SUPPORT. N Engl J Med 2013;368:1929-31.
3. Silverman WA. Retrolenal fibroplasia: a modern parable. New York: Gune & Stratton, 1980.
4. Greenspan JS, Goldsmith JP. Oxygen therapy in preterm infants: hitting the target. Pediatrics 2006;118:1740-1. (Pubitemid 46393832)
5. Carlo WA, Bell EF, Walsh MC. Oxygen saturation targets in extremely preterm infants. N Engl J Med 2013;368:1949-50.